Jody D Berry | University of Manitoba (original) (raw)

Papers by Jody D Berry

All in-text references underlined in blue are linked to publications on ResearchGate, letting you... more All in-text references underlined in blue are linked to publications on ResearchGate, letting you access and read them immediately.

La presente invention concerne des compositions et des methodes de traitement ou de prevention d&... more La presente invention concerne des compositions et des methodes de traitement ou de prevention d'une infection a Clostridium difficile chez un sujet vertebre. Lesdites methodes impliquent l'administration, audit sujet vertebre, d'une quantite d'une composition suffisant a limiter ou supprimer ou prevenir la rechute d'une infection bacterienne a Clostridium difficile et/ou a induire une reponse immunitaire dirigee contre la proteine. L'invention concerne egalement des methodes de traitement ou de prevention d'une infection a Clostridium difficile chez un vertebre.

Drug discovery series, Jul 27, 2005

Polyclonal antibodies have been used from diverse species such as rabbit, goat, sheep, donkey, ch... more Polyclonal antibodies have been used from diverse species such as rabbit, goat, sheep, donkey, chicken, pigs, cats, dogs, minks, and cattle for almost a century as specific and highaffinity probes for a variety of immunological assays in research and clinical laboratories. While polyclonal-pooled immunoglobulin (Ig) is still the gold standard for the treatment of some human diseases, the high purity and specificity of monoclonal antibody will eventually oust these serum preparations from this position; monoclonal antibodies (MAbs) promise to be safer and more specific in therapy. While there

Humana Press eBooks, 2014

Described herein are methods for the successful screening of monoclonal antibodies (mAbs) of the ... more Described herein are methods for the successful screening of monoclonal antibodies (mAbs) of the desired specificities via high-throughput (HTP) homogeneous assay and flow cytometry. We present a combination of screening techniques that allow the scientist to efficiently eliminate nontarget-specific antibody as soon as possible. This compilation of protocols will enable researchers with basic immunology skills to make decisions regarding the design of screening algorithms for the generation of mAbs. Although we have provided an informative overview of both HTP homogeneous assay and flow cytometry, it is imperative for the beginner to acquire fundamental knowledge on how both of these technologies work so as to use these screening strategies effectively.

Journal of Industrial Microbiology & Biotechnology, Jul 1, 1997

Identification of protective determinants from microbial proteins is a necessary step in the rati... more Identification of protective determinants from microbial proteins is a necessary step in the rational design of subunit vaccines. We have previously used a synthetic peptide scan (Pepscan) assay to map a panel of eight neutralizing monoclonal antibodies (mAb; designated as C1.1 to C1.8) to a common motif sequence from Chlamydia trachomatis. In the present study, five of the eight mAbs were used to screen phage random peptide libraries. mAbs C1.1 and C1.3 selected a motif sequence of G-L-X-N-D from a pIII-based phage random peptide library and a motif sequence of G-X-X-N-D from a pVIII-based random peptide library while mAbs C1.6 to C1.8 failed to select recognizable motifs from either of the phage libraries. However, C1.6 to C1.8 bound to the same motif sequence displayed on phage when the appropriate conformational constraints were imposed onto the motif sequence. Thus the specificity of the mAbs identified on Pepscan assays correlates with the mAbs' dependence on local epitope constraints displayed on the phage surface.

Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin... more Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type A.

See next page for additional authors

La presente invention concerne des anticorps monoclonaux et des parties de liaison a l'antige... more La presente invention concerne des anticorps monoclonaux et des parties de liaison a l'antigene de ceux-ci qui se lient specifiquement a un filovirus (par exemple, virus de Marburg (MARV)), y compris des anticorps qui reagissent de facon croisee avec au moins deux filovirus. De tels anticorps sont utiles pour la prevention et le traitement d'une infection par filovirus. L'invention concerne egalement des compositions pharmaceutiques comprenant les anticorps de liaison a MARV, des molecules d'acides nucleiques codant pour ces polypeptides et des methodes de production de ces molecules.

L'invention concerne des reactifs d'anticorps monoclonaux qui reconnaissent le coronaviru... more L'invention concerne des reactifs d'anticorps monoclonaux qui reconnaissent le coronavirus SARS (SARS-HCoV) imperativement necessaires. Dans cette invention, on decrit le developpement et la caracterisation immunochimique des mAbs contre le SARS-HCoV base sur leur specificite, les besoins de liaison et l'activite biologique. Un criblage initial par dosage immunoenzymatique (ELISA), utilisant un virus hautement purifie comme antigene de revetement, entraine une selection de dix-sept mAbs. Cinq mAbs presentent une reactivite immunoblot de type Western avec la proteine de spicule denaturee, dont deux ont demontres la capacite a neutraliser le SARS-HCoV in vitro. Quatre autres mAbs immunoblot negatifs de type Western neutralisent egalement le virus. Ces anticorps sont utiles dans le developpement de tests de diagnostic, de recherches de pathogenicite et de vaccin.

Journal of Virological Methods, Mar 1, 2006

Nipah virus, a zoonotic paramyxovirus which emerged recently was chemically inactivated using bin... more Nipah virus, a zoonotic paramyxovirus which emerged recently was chemically inactivated using binary ethylenimine (BEI). The inactivated virus was concentrated and purified by sucrose gradient centrifugation. The gradient fractions were examined by electron microscopy and Western immunoblot, and gradient fraction containing mainly Nipah matrix (M) and nucleocapsid (N) proteins was used for immunizing BALB/c mice to generate hybridomas. Screening of

Molecular Immunology, 2005

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on ... more Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Cancer, Feb 15, 1987

A panel of monoclonal antibodies including antibodies against neuroectodermal antigens, (UJ13A, U... more A panel of monoclonal antibodies including antibodies against neuroectodermal antigens, (UJ13A, UJ127.11, UJ181.4), leukocytes (2D1), intermediate filament antigens cytokeratin (LE61), Vimentin, Desmin (Labsystems, Helsinki, Finland), myoglobin, and neurofilament (155) antigens were assessed for their use as an adjunct to light microscopy in pediatric pathology, with particular emphasis on the "small round cell" tumors. One hundred thirty-four tumors were studied using immunofluorescence and immunoperoxidase techniques. The differentiation of neuroblastoma from lymphoma proved to have a clear-cut immunologic profile, as did the rhabdomyosarcomas, which showed consistent positivity with neuroectodermal antibody UJ13A and in positive binding with antidesmin. Ewing's sarcoma did not give a clear immunohistologic pattern with these antibodies. This panel was shown to have been a valuable aid to diagnosis in 12% of cases studied. The future use of such a panel for routine diagnostic use is discussed, but it is emphasized that the binding pattern of these tumors is often heterogeneous, and examination in conjunction with conventional histology is essential if the correct conclusions are to be made.

Applied Biosafety, Jun 1, 2006

The authors evaluated vaporized hydrogen peroxide as an alternative to formaldehyde for space bio... more The authors evaluated vaporized hydrogen peroxide as an alternative to formaldehyde for space biodecontamination in a containment level 3 laboratory suite. The laboratory air pressure during the biodecontamination process was maintained at a slightly negative pressure. This was done as a preventive measure to ensure that hazardous vaporized hydrogen peroxide would not escape during the process. Parameters such as temperature, relative humidity, vaporized hydrogen peroxide concentration, and pressure within the laboratory suite were monitored during the biodecontamination. The success of the decontamination process was validated using spores of G. stearothermophilus, the most resistant microorganism to vaporized hydrogen peroxide (

Journal of Immunological Methods, Nov 1, 2004

This protocol describes the application of a polymerase chain reaction to allow the cloning and s... more This protocol describes the application of a polymerase chain reaction to allow the cloning and sequencing of new functional kappa light chain cDNAs from murine hybridomas co-expressing aberrant endogenous kappa chain mRNAs. The presence of kappa light chain aberrant mRNAs can hinder or even prevent determination of the sequence of functional murine kappa light chain cDNAs amplified by PCR from hybridomas. The method described here employs a panel of kappa primers in the presence of molar excess of a primer complementary to the complementary determining region (CDR) 3 of the known aberrant chain sequence. Analysis of the PCR products reveals two bands for some reactions: one the functional, full-length kappa chain cDNA (~400 bp) and another shorter (~100 bp) band corresponding to short aberrant chain kappa CDR3-constant region. The full-length product is gel purified and cloned prior to sequencing and aligned with V-region germline sequences available in NCBI and GenBank databases. This method is used routinely in our laboratory and demonstrates consistency and reliability for sequence determination of kappa light chain V-gene cDNA of mAbs to diverse antigens. This protocol is a rapid and convenient method for determining the sequence of murine V kappa region genes from hybridomas expressing aberrant kappa chain mRNAs.

Veterinary Journal, Sep 1, 2005

Analytical Letters, Dec 31, 2003

... references • Immune libraries: In these libraries, V-genes are derived from the IgG mRNA of B... more ... references • Immune libraries: In these libraries, V-genes are derived from the IgG mRNA of B-cells from animals (mice,[37]37. Andersen, PS, Stryhn, A., Hansen, BE, Fugger, L., Engberg, J. and Buus, S. 1996. A recombinant ...

Journal of Immunoassay & Immunochemistry, Jul 1, 2007

Vaccination with anthrax vaccine adsorbed (AVA) results in the production of protective antigen (... more Vaccination with anthrax vaccine adsorbed (AVA) results in the production of protective antigen (PA) specific antibodies, which play an important protective role against anthrax toxins. Analyzing the specificity of serum antibodies generated in response to AVA vaccination can provide insight into the mechanisms of protective immunity against this important pathogen. The goal of this study was to develop a competitive

Molecular Microbiology, Nov 1, 1996

Chlamydia trachomatis is a nucleotide parasite, being entirely dependent on its host eukaryotic c... more Chlamydia trachomatis is a nucleotide parasite, being entirely dependent on its host eukaryotic cell for a supply of ATP, GTP, and UTP. Chlamydiae are not, however, auxotrophic for CTP, as they are able both to transport CTP from the host and synthesize CTP de novo via a chlamydial CTP synthetase. This study addresses the developmental regulation of CTP synthetase over the course of the C. trachomatis life cycle. Given the distinct life stages of C. trachomatis, analysis of temporal changes in gene expression and regulation of protein activity is the key to unravelling the mechanism of pathogenesis of this bacterium. The results of immunodetection analysis indicate that CTP synthetase is present in C. trachomatis elementary bodies and reticulate bodies and that it is widespread in other chlamydial strains. Reverse transcriptase-polymerase chain reaction (RT-PCR) and metabolic labelling experiments show that CTP synthetase is transcribed and translated primarily during the mid- and late stages of the chlamydial growth cycle. In addition, C. trachomatis CTP synthetase was transcribed with the CTP utilizing enzyme CMP-2-keto-3-deoxy-octanoic acid synthetase (CMP-KDO synthetase) as part of a polycistronic mRNA. The co-expression of these two enzymes suggests a role for CTP synthetase in lipopolysaccharide biosynthesis, potentially channelling CTP directly to CMP-KDO synthetase. The ability of the intact operon to complement CTP synthetase and CMP-KDO deficiencies in mutant Escherichia coli strains indicates that both enzymes are efficiently translated from a single messenger RNA. Kinetic analysis revealed that the C. trachomatis CTP synthetase possessed co-operativity patterns typical of both prokaryotic and eukaryotic CTP synthetases. However, the K(m) of the enzyme for UTP was lower than that of E. coli CTP synthetase, presumably in response to the low intracellular concentration of this nucleotide in C. trachomatis.

New Biotechnology, Sep 1, 2011

Antibody preparations have a long history of providing protection from infectious diseases. Altho... more Antibody preparations have a long history of providing protection from infectious diseases. Although antibodies remain the only natural host-derived defense mechanism capable of completely preventing infection, as products, they compete against inexpensive therapeutics such as antibiotics, small molecule inhibitors and active vaccines. The continued discovery in the monoclonal antibody (mAb) field of leads with broadened cross neutralization of viruses and demonstrable synergy of antibody with antibiotics for bacterial diseases, clearly show that innovation remains. The commercial success of mAbs in chronic disease has not been paralleled in infectious diseases for several reasons. Infectious disease immunotherapeutics are limited in scope as endemic diseases necessitate active vaccine development. Also, the complexity of these small markets draws the interest of niche companies rather than big pharmaceutical corporations. Lastly, the cost of goods for mAb therapeutics is inherently high for infectious agents due to the need for antibody cocktails, which better mimic polyclonal immunoglobulin preparations and prevent antigenic escape. In cases where vaccine or convalescent populations are available, current polyclonal hyperimmune immunoglobulin preparations (pIgG), with modern and highly efficient purification technology and standardized assays for potency, can make economic sense. Recent innovations to broaden the potency of mAb therapies, while reducing cost of production, are discussed herein. On the basis of centuries of effective use of Ab treatments, and with growing immunocompromised populations, the question is not whether antibodies have a bright future for infectious agents, but rather what formats are cost effective and generate safe and efficacious treatments to satisfy regulatory approval. Contents Anti-infective antibodies: new opportunities for a proven technology. .

medRxiv (Cold Spring Harbor Laboratory), Feb 4, 2022